Today we welcome back friend of the show Jane Myles, VP Innovation at Curebase. Decentralized clinical trials are talked about so much nowadays but, all too often, we are left to guess whether they perform better or worse than hybrid and brick and mortar trials. In this episode we examine a real life example of a DCT in action including metrics against hybrid and brick and mortar sites in addition to addressing some of the myths that surround DCTs.